Zentalis Pharmaceuticals, Inc.

NASDAQ:ZNTL

Biotechnology

Healthcare
$1.36 +0.83%

+$0.03 today

Market cap
$133.64M
Beta
1.98
P/E (TTM)
-2.1
EPS (TTM)
-$1.77
52W Low $1.13High $6.95

Volume 1.21M

Average 2.00M

ZNTL Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Zentalis Pharmaceuticals, Inc.NASDAQ: ZNTL

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $151K fell 42.4% year over year, ahead of the -48.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 3.8% from the prior quarter. Over 3 fiscal years it compounded at -19.7% a year.

Context

  • Depreciation & amortization increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -42.4% holds above the trailing-twelve-month pace of -48.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$151K-3.8% QoQ
Last fiscal yearDec 2025
$739K-42.7% YoY
LTMMar 2026
$628K-48.8% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-42.4%——
1 year-42.7%——
3-year CAGR-19.7%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
739K USD
Year-over-year change
-42.7%
4-year CAGR
+8.0%

Depreciation & Amortization vs competitors

How ZNTL compares with its peers on the latest reported figures

  • ZNTL's LTM Mar 2026 depreciation & amortization of $628K is the 8th largest of the 11 companies compared; the peer median is $2.1M.
  • Its year-over-year change of -48.8% is the 9th highest of 11, against a peer median of -17.3%.
  • Over three fiscal years its annual growth of -19.7% compares with a peer median of +1.9%.
ZNTL Competitors Peer median
Depreciation & Amortization for ZNTL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$6.94M -7.1%-22.5%4.4%
STROSutro Biopharma, Inc.LTM Mar 2026$6.7M -8.9%+8.8%6.7%
STTKShattuck Labs, Inc.LTM Mar 2026$3.64M -3.9%+6.3%364.3%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$2.71M +9.6%+30.9%—
DTILPrecision BioSciences, Inc.LTM Mar 2026$2.69M -30.3%-32.6%6.0%
PLRXPliant Therapeutics, Inc.LTM Mar 2026$1.51M -26.6%-2.4%—
ALXOALX Oncology Holdings Inc.LTM Mar 2026$645K -25.8%+27.3%—
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$628K -48.8%-19.7%—
IMMXImmix Biopharma, Inc.LTM Mar 2026$436.09K +189.3%+454.8%—
WHWKWhitehawk Therapeutics IncLTM Dec 2025$79K -59.1%-20.8%1.1%
TILInstil Bio, Inc.LTM Mar 2026$48K -98.5%-55.3%—
Peer median (excluding ZNTL) $2.1M-17.3%+1.9%6.0%

Competitors are the stored peer set for ZNTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(166.09M)(237.11M)(292.19M)(165.87M)(137.06M)
Depreciation & Amortization544K1.43M1.39M1.29M739K
Deferred Income Tax(2.51M)(769K)(853K)00
Stock-Based Compensation35.74M46.84M54.82M67.27M20.72M
Change in Working Capital16.61M13.25M5.86M(16.54M)(9.12M)
Accounts Receivables413K00(5M)5M
Inventory00000
Accounts Payables13.96M15.53M10.92M(18.02M)(17.32M)
Other Working Capital2.23M(2.28M)(5.06M)6.48M3.19M
Other Non-Cash Items(38.38M)12.61M23.15M(57.01M)(526K)
Operating Cash Flow(154.09M)(163.75M)(207.82M)(170.86M)(125.25M)
Capital Expenditures(6.11M)(2.55M)(583K)(221K)0
Acquisitions (Net)(14.32M)111.63K065K0
Purchases of Investments(363.51M)(533.16M)(549.18M)(127.96M)(139.49M)
Sales of Investments365.82M421.53M505.31M304.68M270.41M
Other Investing Activities0(111.63K)00698K
Investing Cash Flow(18.12M)(114.18M)(44.46M)176.56M131.62M
Debt Repayment00000
Common Stock Issued179.67M261.04M237.3M349K(4.28M)
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.15M)00(241K)0
Financing Cash Flow178.52M261.04M237.3M108K(4.28M)
Effect of Forex Changes00000
Net Change in Cash6.31M(16.89M)(14.98M)5.81M2.09M
Free Cash Flow(160.2M)(166.3M)(208.41M)(171.08M)(125.25M)

Zentalis Pharmaceuticals, Inc.

NASDAQ:ZNTL

Intrinsic Alpha fair value

Locked

Current Price

$1.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.